nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—melanoma	0.325	0.529	CbGaD
Bismuth Subsalicylate—ALB—melanoma	0.289	0.471	CbGaD
Bismuth Subsalicylate—ALB—Vemurafenib—melanoma	0.0991	1	CbGbCtD
Bismuth Subsalicylate—Skin papilloma—Vemurafenib—melanoma	0.0081	0.0789	CcSEcCtD
Bismuth Subsalicylate—Localized exfoliation—Bleomycin—melanoma	0.00594	0.0578	CcSEcCtD
Bismuth Subsalicylate—TF—blood vessel—melanoma	0.0057	0.138	CbGeAlD
Bismuth Subsalicylate—PTGS2—leg—melanoma	0.00379	0.0918	CbGeAlD
Bismuth Subsalicylate—PTGS2—hindlimb—melanoma	0.00338	0.082	CbGeAlD
Bismuth Subsalicylate—TF—eye—melanoma	0.00303	0.0735	CbGeAlD
Bismuth Subsalicylate—TF—retina—melanoma	0.00301	0.0729	CbGeAlD
Bismuth Subsalicylate—PTGS2—appendage—melanoma	0.0029	0.0703	CbGeAlD
Bismuth Subsalicylate—TF—skin of body—melanoma	0.00264	0.064	CbGeAlD
Bismuth Subsalicylate—PTGS2—skin epidermis—melanoma	0.00241	0.0585	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Carmustine—melanoma	0.00201	0.0196	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Temozolomide—melanoma	0.00191	0.0186	CcSEcCtD
Bismuth Subsalicylate—Duodenal ulcer—Docetaxel—melanoma	0.00186	0.0181	CcSEcCtD
Bismuth Subsalicylate—PTGS1—endothelium—melanoma	0.00183	0.0444	CbGeAlD
Bismuth Subsalicylate—Extravasation—Bleomycin—melanoma	0.00183	0.0179	CcSEcCtD
Bismuth Subsalicylate—PTGS2—endothelium—melanoma	0.00175	0.0425	CbGeAlD
Bismuth Subsalicylate—TF—head—melanoma	0.00172	0.0417	CbGeAlD
Bismuth Subsalicylate—Extravasation—Dactinomycin—melanoma	0.00171	0.0166	CcSEcCtD
Bismuth Subsalicylate—PTGS1—blood vessel—melanoma	0.00169	0.041	CbGeAlD
Bismuth Subsalicylate—PTGS2—blood vessel—melanoma	0.00162	0.0392	CbGeAlD
Bismuth Subsalicylate—Extravasation—Carmustine—melanoma	0.0016	0.0156	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Bleomycin—melanoma	0.00153	0.0149	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Temozolomide—melanoma	0.00142	0.0138	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Dactinomycin—melanoma	0.00136	0.0133	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Bleomycin—melanoma	0.00135	0.0131	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Carmustine—melanoma	0.00133	0.013	CcSEcCtD
Bismuth Subsalicylate—Heartburn—Docetaxel—melanoma	0.0013	0.0127	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Docetaxel—melanoma	0.00129	0.0126	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Temozolomide—melanoma	0.00129	0.0125	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Dactinomycin—melanoma	0.00126	0.0122	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Vemurafenib—melanoma	0.00125	0.0122	CcSEcCtD
Bismuth Subsalicylate—TF—lymph node—melanoma	0.00121	0.0292	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Carmustine—melanoma	0.00118	0.0115	CcSEcCtD
Bismuth Subsalicylate—Erythema—Vemurafenib—melanoma	0.00115	0.0112	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Vemurafenib—melanoma	0.00113	0.011	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Dactinomycin—melanoma	0.0011	0.0108	CcSEcCtD
Bismuth Subsalicylate—Deafness—Temozolomide—melanoma	0.00109	0.0107	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Docetaxel—melanoma	0.00103	0.01	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Carmustine—melanoma	0.00102	0.00991	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Docetaxel—melanoma	0.000942	0.00918	CcSEcCtD
Bismuth Subsalicylate—Infection—Vemurafenib—melanoma	0.000935	0.00911	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Docetaxel—melanoma	0.000856	0.00834	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Docetaxel—melanoma	0.000819	0.00798	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Vemurafenib—melanoma	0.000818	0.00797	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vemurafenib—melanoma	0.000805	0.00784	CcSEcCtD
Bismuth Subsalicylate—Lightheadedness—Docetaxel—melanoma	0.000802	0.00782	CcSEcCtD
Bismuth Subsalicylate—PTGS1—skin of body—melanoma	0.000783	0.019	CbGeAlD
Bismuth Subsalicylate—Weight increased—Temozolomide—melanoma	0.00077	0.0075	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Docetaxel—melanoma	0.000756	0.00736	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Dactinomycin—melanoma	0.000749	0.00729	CcSEcCtD
Bismuth Subsalicylate—PTGS2—skin of body—melanoma	0.000748	0.0181	CbGeAlD
Bismuth Subsalicylate—Body temperature increased—Vemurafenib—melanoma	0.000744	0.00725	CcSEcCtD
Bismuth Subsalicylate—Deafness—Docetaxel—melanoma	0.000728	0.00709	CcSEcCtD
Bismuth Subsalicylate—PTGS1—mammalian vulva—melanoma	0.000714	0.0173	CbGeAlD
Bismuth Subsalicylate—Erythema multiforme—Dactinomycin—melanoma	0.000708	0.0069	CcSEcCtD
Bismuth Subsalicylate—Erythema—Bleomycin—melanoma	0.000699	0.00681	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Carmustine—melanoma	0.000697	0.00679	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Temozolomide—melanoma	0.000677	0.0066	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Temozolomide—melanoma	0.000674	0.00656	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Vemurafenib—melanoma	0.000666	0.00649	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Docetaxel—melanoma	0.000664	0.00647	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Docetaxel—melanoma	0.000654	0.00637	CcSEcCtD
Bismuth Subsalicylate—Erythema—Dactinomycin—melanoma	0.000652	0.00635	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vemurafenib—melanoma	0.000644	0.00628	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Temozolomide—melanoma	0.00064	0.00624	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Temozolomide—melanoma	0.000631	0.00615	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—melanoma	0.000627	0.0152	CbGeAlD
Bismuth Subsalicylate—Dizziness—Vemurafenib—melanoma	0.000623	0.00607	CcSEcCtD
Bismuth Subsalicylate—Erythema—Carmustine—melanoma	0.00061	0.00594	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vemurafenib—melanoma	0.000599	0.00583	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Docetaxel—melanoma	0.000595	0.00579	CcSEcCtD
Bismuth Subsalicylate—Rash—Vemurafenib—melanoma	0.000594	0.00578	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vemurafenib—melanoma	0.000593	0.00578	CcSEcCtD
Bismuth Subsalicylate—Headache—Vemurafenib—melanoma	0.00059	0.00575	CcSEcCtD
Bismuth Subsalicylate—Erythema—Temozolomide—melanoma	0.00059	0.00574	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Temozolomide—melanoma	0.000577	0.00562	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Bleomycin—melanoma	0.000575	0.0056	CcSEcCtD
Bismuth Subsalicylate—Oedema—Bleomycin—melanoma	0.00057	0.00556	CcSEcCtD
Bismuth Subsalicylate—Infection—Bleomycin—melanoma	0.000567	0.00552	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vemurafenib—melanoma	0.000559	0.00545	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Bleomycin—melanoma	0.000544	0.0053	CcSEcCtD
Bismuth Subsalicylate—Oedema—Dactinomycin—melanoma	0.000532	0.00518	CcSEcCtD
Bismuth Subsalicylate—Infection—Dactinomycin—melanoma	0.000528	0.00515	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Docetaxel—melanoma	0.000512	0.00499	CcSEcCtD
Bismuth Subsalicylate—PTGS1—head—melanoma	0.000511	0.0124	CbGeAlD
Bismuth Subsalicylate—Anorexia—Dactinomycin—melanoma	0.000507	0.00494	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Carmustine—melanoma	0.000502	0.00489	CcSEcCtD
Bismuth Subsalicylate—Oedema—Carmustine—melanoma	0.000498	0.00485	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Bleomycin—melanoma	0.000496	0.00483	CcSEcCtD
Bismuth Subsalicylate—Infection—Carmustine—melanoma	0.000495	0.00482	CcSEcCtD
Bismuth Subsalicylate—PTGS2—head—melanoma	0.000488	0.0118	CbGeAlD
Bismuth Subsalicylate—Pain—Bleomycin—melanoma	0.000488	0.00475	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Temozolomide—melanoma	0.000485	0.00473	CcSEcCtD
Bismuth Subsalicylate—Oedema—Temozolomide—melanoma	0.000481	0.00469	CcSEcCtD
Bismuth Subsalicylate—Infection—Temozolomide—melanoma	0.000478	0.00466	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Carmustine—melanoma	0.000475	0.00462	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Docetaxel—melanoma	0.000473	0.00461	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Bleomycin—melanoma	0.00047	0.00458	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dactinomycin—melanoma	0.000462	0.00451	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Temozolomide—melanoma	0.000459	0.00447	CcSEcCtD
Bismuth Subsalicylate—Pain—Dactinomycin—melanoma	0.000455	0.00443	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Bleomycin—melanoma	0.000453	0.00441	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Bleomycin—melanoma	0.000451	0.00439	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Docetaxel—melanoma	0.00045	0.00439	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Carmustine—melanoma	0.000443	0.00431	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Dactinomycin—melanoma	0.000438	0.00427	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Carmustine—melanoma	0.000433	0.00422	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Temozolomide—melanoma	0.000428	0.00417	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Docetaxel—melanoma	0.000426	0.00415	CcSEcCtD
Bismuth Subsalicylate—Constipation—Carmustine—melanoma	0.000426	0.00415	CcSEcCtD
Bismuth Subsalicylate—Pain—Carmustine—melanoma	0.000426	0.00415	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Temozolomide—melanoma	0.000424	0.00413	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Dactinomycin—melanoma	0.00042	0.0041	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Temozolomide—melanoma	0.000418	0.00407	CcSEcCtD
Bismuth Subsalicylate—Pain—Temozolomide—melanoma	0.000411	0.00401	CcSEcCtD
Bismuth Subsalicylate—Constipation—Temozolomide—melanoma	0.000411	0.00401	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Carmustine—melanoma	0.00041	0.004	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Bleomycin—melanoma	0.000404	0.00393	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Temozolomide—melanoma	0.000396	0.00386	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Carmustine—melanoma	0.000394	0.00383	CcSEcCtD
Bismuth Subsalicylate—Erythema—Docetaxel—melanoma	0.000392	0.00382	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Docetaxel—melanoma	0.000384	0.00374	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Temozolomide—melanoma	0.000382	0.00372	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Temozolomide—melanoma	0.00038	0.00371	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Dactinomycin—melanoma	0.000364	0.00355	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Bleomycin—melanoma	0.000363	0.00353	CcSEcCtD
Bismuth Subsalicylate—Rash—Bleomycin—melanoma	0.00036	0.0035	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Bleomycin—melanoma	0.000359	0.0035	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—melanoma	0.000358	0.00867	CbGeAlD
Bismuth Subsalicylate—PTGS2—lymph node—melanoma	0.000342	0.00828	CbGeAlD
Bismuth Subsalicylate—Diarrhoea—Carmustine—melanoma	0.000341	0.00332	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Temozolomide—melanoma	0.00034	0.00332	CcSEcCtD
Bismuth Subsalicylate—Nausea—Bleomycin—melanoma	0.000339	0.0033	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Dactinomycin—melanoma	0.000338	0.0033	CcSEcCtD
Bismuth Subsalicylate—Rash—Dactinomycin—melanoma	0.000335	0.00327	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Carmustine—melanoma	0.000329	0.00321	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Temozolomide—melanoma	0.000329	0.00321	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Docetaxel—melanoma	0.000323	0.00314	CcSEcCtD
Bismuth Subsalicylate—Oedema—Docetaxel—melanoma	0.00032	0.00312	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Temozolomide—melanoma	0.000318	0.0031	CcSEcCtD
Bismuth Subsalicylate—Infection—Docetaxel—melanoma	0.000318	0.0031	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Carmustine—melanoma	0.000317	0.00308	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dactinomycin—melanoma	0.000316	0.00308	CcSEcCtD
Bismuth Subsalicylate—Rash—Carmustine—melanoma	0.000314	0.00306	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Carmustine—melanoma	0.000314	0.00306	CcSEcCtD
Bismuth Subsalicylate—Headache—Carmustine—melanoma	0.000312	0.00304	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Temozolomide—melanoma	0.000306	0.00298	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Docetaxel—melanoma	0.000305	0.00297	CcSEcCtD
Bismuth Subsalicylate—Rash—Temozolomide—melanoma	0.000303	0.00296	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Temozolomide—melanoma	0.000303	0.00295	CcSEcCtD
Bismuth Subsalicylate—Headache—Temozolomide—melanoma	0.000301	0.00294	CcSEcCtD
Bismuth Subsalicylate—Nausea—Carmustine—melanoma	0.000296	0.00288	CcSEcCtD
Bismuth Subsalicylate—Nausea—Temozolomide—melanoma	0.000286	0.00278	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Docetaxel—melanoma	0.000284	0.00277	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Docetaxel—melanoma	0.000282	0.00274	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Docetaxel—melanoma	0.000278	0.00271	CcSEcCtD
Bismuth Subsalicylate—Constipation—Docetaxel—melanoma	0.000274	0.00267	CcSEcCtD
Bismuth Subsalicylate—Pain—Docetaxel—melanoma	0.000274	0.00267	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Docetaxel—melanoma	0.000264	0.00257	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Docetaxel—melanoma	0.000253	0.00246	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Docetaxel—melanoma	0.000226	0.00221	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Docetaxel—melanoma	0.000219	0.00213	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Docetaxel—melanoma	0.000212	0.00206	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Docetaxel—melanoma	0.000203	0.00198	CcSEcCtD
Bismuth Subsalicylate—Rash—Docetaxel—melanoma	0.000202	0.00197	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Docetaxel—melanoma	0.000202	0.00196	CcSEcCtD
Bismuth Subsalicylate—Headache—Docetaxel—melanoma	0.0002	0.00195	CcSEcCtD
Bismuth Subsalicylate—Nausea—Docetaxel—melanoma	0.00019	0.00185	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—FASN—melanoma	4.62e-05	0.000324	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TNF—melanoma	4.61e-05	0.000323	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—IL6—melanoma	4.6e-05	0.000322	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SPARC—melanoma	4.59e-05	0.000322	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—F2R—melanoma	4.59e-05	0.000322	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—LUM—melanoma	4.58e-05	0.000321	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TNF—melanoma	4.51e-05	0.000316	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—FN1—melanoma	4.5e-05	0.000315	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SDHD—melanoma	4.5e-05	0.000315	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—BSG—melanoma	4.5e-05	0.000315	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CSPG4—melanoma	4.5e-05	0.000315	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HPSE—melanoma	4.5e-05	0.000315	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIP4K2A—melanoma	4.43e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC6A11—melanoma	4.43e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CUBN—melanoma	4.41e-05	0.000309	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GPAM—melanoma	4.35e-05	0.000305	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CG—melanoma	4.31e-05	0.000302	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTAP—melanoma	4.31e-05	0.000302	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	4.3e-05	0.000301	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HSPA5—melanoma	4.29e-05	0.000301	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CSPG4—melanoma	4.26e-05	0.000299	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—EGF—melanoma	4.26e-05	0.000298	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	4.22e-05	0.000295	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	4.21e-05	0.000295	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—GAB2—melanoma	4.2e-05	0.000294	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—GNA11—melanoma	4.2e-05	0.000294	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—RPS3—melanoma	4.19e-05	0.000294	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SKI—melanoma	4.13e-05	0.000289	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	4.11e-05	0.000288	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	4.07e-05	0.000285	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	4.05e-05	0.000283	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—melanoma	3.98e-05	0.000279	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	3.97e-05	0.000278	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	3.96e-05	0.000278	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HDAC2—melanoma	3.95e-05	0.000276	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IGF1—melanoma	3.94e-05	0.000276	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	3.94e-05	0.000276	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ITGA4—melanoma	3.9e-05	0.000273	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—GNAQ—melanoma	3.9e-05	0.000273	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CD44—melanoma	3.9e-05	0.000273	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNB1—melanoma	3.87e-05	0.000271	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PHGDH—melanoma	3.84e-05	0.000269	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—LUM—melanoma	3.84e-05	0.000269	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PLCB4—melanoma	3.81e-05	0.000267	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CD—melanoma	3.79e-05	0.000265	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA1—melanoma	3.78e-05	0.000265	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HPSE—melanoma	3.76e-05	0.000264	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—FASN—melanoma	3.74e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—IL6—melanoma	3.72e-05	0.000261	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PLA2G6—melanoma	3.7e-05	0.000259	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CUBN—melanoma	3.7e-05	0.000259	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SYK—melanoma	3.67e-05	0.000257	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL6—melanoma	3.64e-05	0.000255	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ITGAV—melanoma	3.6e-05	0.000252	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT3—melanoma	3.6e-05	0.000252	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC6A11—melanoma	3.58e-05	0.000251	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIP4K2A—melanoma	3.58e-05	0.000251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	3.58e-05	0.000251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SDHD—melanoma	3.57e-05	0.00025	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CSPG4—melanoma	3.57e-05	0.00025	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—BSG—melanoma	3.57e-05	0.00025	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA2—melanoma	3.52e-05	0.000246	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC5A5—melanoma	3.5e-05	0.000245	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTAP—melanoma	3.48e-05	0.000244	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GPAM—melanoma	3.46e-05	0.000242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HDAC6—melanoma	3.41e-05	0.000239	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	3.41e-05	0.000239	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	3.39e-05	0.000237	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—VCAN—melanoma	3.33e-05	0.000233	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CB—melanoma	3.3e-05	0.000231	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—melanoma	3.29e-05	0.000231	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ITGB1—melanoma	3.27e-05	0.000229	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NPPA—melanoma	3.23e-05	0.000226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	3.22e-05	0.000226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	3.22e-05	0.000226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—VCAN—melanoma	3.15e-05	0.000221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	3.15e-05	0.000221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—WNT5A—melanoma	3.13e-05	0.000219	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—LUM—melanoma	3.11e-05	0.000218	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PHGDH—melanoma	3.11e-05	0.000218	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—melanoma	3.07e-05	0.000215	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HPSE—melanoma	3.05e-05	0.000213	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	3.04e-05	0.000213	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—melanoma	3.04e-05	0.000213	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL2—melanoma	3.03e-05	0.000212	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HGF—melanoma	2.99e-05	0.00021	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CUBN—melanoma	2.99e-05	0.000209	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CSF2—melanoma	2.96e-05	0.000207	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PLA2G6—melanoma	2.94e-05	0.000206	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SDHD—melanoma	2.89e-05	0.000202	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CSPG4—melanoma	2.89e-05	0.000202	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—BSG—melanoma	2.89e-05	0.000202	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ITGB3—melanoma	2.84e-05	0.000199	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PRKCA—melanoma	2.84e-05	0.000199	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP17A1—melanoma	2.81e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GPAM—melanoma	2.8e-05	0.000196	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	2.8e-05	0.000196	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.77e-05	0.000194	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—ALB—melanoma	2.73e-05	0.000191	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—melanoma	2.7e-05	0.000189	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCB1—melanoma	2.67e-05	0.000187	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GNA11—melanoma	2.65e-05	0.000186	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—VCAN—melanoma	2.64e-05	0.000185	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—RAC1—melanoma	2.63e-05	0.000184	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—FASN—melanoma	2.59e-05	0.000182	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—melanoma	2.58e-05	0.000181	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC5A5—melanoma	2.55e-05	0.000179	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MMP1—melanoma	2.54e-05	0.000178	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GAB2—melanoma	2.51e-05	0.000176	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.5e-05	0.000175	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CDK2—melanoma	2.5e-05	0.000175	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GNAQ—melanoma	2.46e-05	0.000173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CD44—melanoma	2.46e-05	0.000173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FASN—melanoma	2.46e-05	0.000172	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	2.44e-05	0.000171	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.41e-05	0.000169	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.41e-05	0.000169	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.39e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PLA2G6—melanoma	2.38e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP1B1—melanoma	2.36e-05	0.000165	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FOXO4—melanoma	2.36e-05	0.000165	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HDAC2—melanoma	2.36e-05	0.000165	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CXCR4—melanoma	2.36e-05	0.000165	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD44—melanoma	2.33e-05	0.000164	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—FN1—melanoma	2.32e-05	0.000163	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	2.32e-05	0.000162	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NOS2—melanoma	2.29e-05	0.000161	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.28e-05	0.00016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP17A1—melanoma	2.23e-05	0.000156	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CG—melanoma	2.22e-05	0.000156	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.2e-05	0.000154	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EGF—melanoma	2.2e-05	0.000154	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—ALB—melanoma	2.17e-05	0.000152	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT3—melanoma	2.15e-05	0.000151	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—VCAN—melanoma	2.14e-05	0.00015	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GNA11—melanoma	2.1e-05	0.000147	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.08e-05	0.000146	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—FASN—melanoma	2.06e-05	0.000144	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IGF1—melanoma	2.03e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC5A5—melanoma	2.02e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.02e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	2.01e-05	0.000141	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CD44—melanoma	1.96e-05	0.000137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GNAQ—melanoma	1.96e-05	0.000137	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CD—melanoma	1.95e-05	0.000137	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.95e-05	0.000137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCB1—melanoma	1.94e-05	0.000136	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.91e-05	0.000134	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERBB4—melanoma	1.9e-05	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN2B—melanoma	1.89e-05	0.000132	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP1B1—melanoma	1.87e-05	0.000131	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD86—melanoma	1.82e-05	0.000128	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP17A1—melanoma	1.8e-05	0.000126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PRKCA—melanoma	1.79e-05	0.000125	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.78e-05	0.000125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ERCC2—melanoma	1.78e-05	0.000124	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGF1—melanoma	1.77e-05	0.000124	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFRA—melanoma	1.71e-05	0.00012	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GNA11—melanoma	1.7e-05	0.000119	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CB—melanoma	1.7e-05	0.000119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRKCA—melanoma	1.7e-05	0.000119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERCC2—melanoma	1.68e-05	0.000118	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—FASN—melanoma	1.67e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAP2K2—melanoma	1.66e-05	0.000116	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.65e-05	0.000116	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	1.64e-05	0.000115	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC5A5—melanoma	1.64e-05	0.000115	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CD44—melanoma	1.58e-05	0.000111	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GNAQ—melanoma	1.58e-05	0.000111	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—melanoma	1.58e-05	0.00011	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HLA-A—melanoma	1.58e-05	0.00011	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—RAC1—melanoma	1.57e-05	0.00011	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2—melanoma	1.56e-05	0.000109	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.55e-05	0.000109	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCB1—melanoma	1.54e-05	0.000108	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.53e-05	0.000108	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP1B1—melanoma	1.52e-05	0.000106	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HIF1A—melanoma	1.51e-05	0.000106	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.47e-05	0.000103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PRKCA—melanoma	1.42e-05	9.95e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ERCC2—melanoma	1.41e-05	9.87e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CG—melanoma	1.4e-05	9.82e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOS2—melanoma	1.37e-05	9.61e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOTCH1—melanoma	1.36e-05	9.52e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—melanoma	1.35e-05	9.48e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.34e-05	9.38e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD80—melanoma	1.33e-05	9.33e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APC—melanoma	1.33e-05	9.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KIT—melanoma	1.33e-05	9.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—melanoma	1.33e-05	9.3e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGF—melanoma	1.31e-05	9.2e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—melanoma	1.31e-05	9.19e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK3—melanoma	1.26e-05	8.8e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BRAF—melanoma	1.25e-05	8.75e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCB1—melanoma	1.25e-05	8.75e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CD—melanoma	1.23e-05	8.63e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALB—melanoma	1.22e-05	8.52e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK1—melanoma	1.2e-05	8.38e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAP2K1—melanoma	1.18e-05	8.24e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CD—melanoma	1.17e-05	8.18e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.17e-05	8.18e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PRKCA—melanoma	1.15e-05	8.05e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ERCC2—melanoma	1.14e-05	7.99e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—melanoma	1.13e-05	7.91e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGF2—melanoma	1.12e-05	7.84e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CG—melanoma	1.11e-05	7.8e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CB—melanoma	1.07e-05	7.53e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—melanoma	1.07e-05	7.53e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—melanoma	1.06e-05	7.46e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MDM2—melanoma	1.05e-05	7.33e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—melanoma	1.04e-05	7.27e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERBB2—melanoma	1.03e-05	7.23e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CB—melanoma	1.02e-05	7.13e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD4—melanoma	1.02e-05	7.12e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—melanoma	1e-05	7.03e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CD—melanoma	9.78e-06	6.85e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALB—melanoma	9.66e-06	6.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—melanoma	9.6e-06	6.72e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1B—melanoma	9.56e-06	6.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.44e-06	6.62e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—melanoma	9.28e-06	6.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—melanoma	9.03e-06	6.32e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CG—melanoma	9e-06	6.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1A—melanoma	8.82e-06	6.18e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—melanoma	8.8e-06	6.16e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—melanoma	8.69e-06	6.09e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CB—melanoma	8.53e-06	5.97e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—melanoma	8.47e-06	5.94e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CD—melanoma	7.91e-06	5.55e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT3—melanoma	7.87e-06	5.51e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—melanoma	7.85e-06	5.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAPK3—melanoma	7.52e-06	5.27e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—melanoma	7.37e-06	5.16e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—melanoma	7.31e-06	5.12e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAPK1—melanoma	7.15e-06	5.01e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—melanoma	7.15e-06	5.01e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CB—melanoma	6.9e-06	4.83e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—melanoma	6.84e-06	4.79e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—melanoma	6.76e-06	4.73e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—melanoma	6.55e-06	4.59e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—melanoma	6.21e-06	4.35e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—melanoma	5.96e-06	4.18e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—melanoma	5.74e-06	4.02e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6—melanoma	5.5e-06	3.85e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—melanoma	5.35e-06	3.75e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—melanoma	5.2e-06	3.64e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—melanoma	5.07e-06	3.55e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—melanoma	4.25e-06	2.98e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—melanoma	4.21e-06	2.95e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—melanoma	3.44e-06	2.41e-05	CbGpPWpGaD
